The risk of bronchiolitis obliterans syndrome is reduced in lung transplant patients who receive mycophenolate mofetil based immunosuppression

Dunitz, Jordan M.; Hertz, Marshall I.; Savik, S. K.; Park, S.J

doi:10.1016/s1053-2498(02)00934-8

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large, single-center retrospective study of 303 LTRs compared the risk of developing Ն stage 2 BOS in 105 patients receiving MMF as part of immunosuppression immediately posttransplant compared with 108 patients who never received MMF. 263 Those receiving MMF were half as likely to develop BOS 2 (odds ratio 0.51) as compared with non-MMF patients (95% CI 0.27, 0.99; p = 0.049). Survival was similar in the two groups.…”

Section: Mycophenolate Mofetilmentioning

confidence: 91%

Bronchiolitis Obliterans Syndrome Complicating Lung or Heart-Lung Transplantation

Belperio

Lake

Tazelaar³

et al. 2003

Seminars in Respiratory and Critical Care Medicine

View full text Add to dashboard Cite

Lung transplantation is a therapeutic option for patients with end stage lung diseases, but long-term survival remains poor, primarily due to chronic allograft rejection. Bronchiolitis obliterans (BO), a fibrotic process resulting in progressive narrowing of bronchiolar lumens and airflow obstruction, is a manifestation of chronic allograft rejection. The term obliterative bronchiolitis ( OB) is synonymous. Once bronchiolitis obliterans syndrome (BOS) develops, progressive decline in pulmonary function is typical; most patients die of respiratory failure within 5 years of onset. The diagnosis of BOS is usually made by clinical, physiological, and radiographic parameters. The dominant risk factor for BOS is acute allograft rejection, but additional factors play contributory roles [e.g., infections; human leukocyte antigen (HLA) mismatching; and injury to the allograft or airways]. The pathogenesis of BOS is complex and involves myriad cell types (both immune and nonimmune) and release of diverse cytokines and chemokines. Unfortunately, current therapies for BOS are of unproven value. A greater understanding of the pathogenic mechanisms operative in BOS are critical to developing novel strategies to treat and prevent this devastating complication.

show abstract

Section: Mycophenolate Mofetilmentioning

confidence: 91%